Physician profile
Thomas Janicki
NPI 1730285248
$3,128.34
in general payments reported to CMS, 2019-2025
31 companies · $815 in 2025
The $815 reported for 2025 was more than what 89% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $654 · 2020: $240 · 2021: $196 · 2022: $460 · 2023: $430 · 2024: $334 · 2025: $815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,565 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,565.08 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $393.93 | 2019-2025 | Veozah |
| Abbvie INC. | $374.91 | 2019-2025 | |
| Pfizer INC. | $262.55 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $254.76 | 2019-2025 | Gardasil 9, Gardasil |
| Sage Therapeutics, LLC | $215.78 | 2022-2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $199.36 | 2019-2025 | |
| Hologic Sales and Service, LLC | $197.01 | 2019-2025 | Acessa Provu System, Myosure Tissue Removal Device, Novasure |
| Mayne Pharma Commercial LLC | $158.32 | 2021-2025 | |
| Exeltis, USA INC. | $113.93 | 2023-2025 | Slynd, Solosec |
| Therapeuticsmd, INC. | $109.40 | 2019-2022 | |
| Agile Therapeutics, INC. | $100.18 | 2021-2022 | |
| Exact Sciences Corporation | $94.24 | 2025 | The Cologuard Plus Collection Kit |
| Sumitomo Pharma America, INC. | $90.58 | 2023-2025 | Myfembree, Gemtesa |
| Lupin INC. | $71.98 | 2019-2020 | |
| Gynesonics, INC. | $57.50 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $51.04 | 2025 | Nexplanon |
| Amag Pharmaceuticals, INC. | $39.65 | 2019 | |
| Myovant Sciences INC. | $38.64 | 2021-2022 | |
| Mylan Pharmaceuticals INC. | $37.02 | 2019-2021 | |
| Millicent US INC | $36.21 | 2024 | Intrarosa, Femring |
| Aspira Women'S Health INC | $35.00 | 2022 | |
| Ethicon US, LLC | $30.44 | 2022 | |
| Allergan, INC. | $26.11 | 2019 | |
| Optumhealth Care Solutions, LLC | $23.74 | 2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Amgen INC. | $23.13 | 2019 | |
| Supernus Pharmaceuticals, INC. | $22.81 | 2025 | Qelbree |
| Avion Pharmaceuticals | $15.26 | 2019 | |
| Roche Diagnostics Corporation | $14.95 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $14.52 | 2023 | Exparel |
| Meditrina | $14.08 | 2021 | |
| Duchesnay USA Incorporated | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Janicki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.